High density lipoproteins (HDL) and the oxidative hypothesis of atherosclerosis

Clinical Chemistry and Laboratory Medicine

Volumn 37, Issue 10, 1999, Pages 939-948

  Bonnefont Rousselot, Dominique ^a,b   Thérond, Patrice ^a   Beaudeux, Jean Louis ^a   Peynet, Jacqueline ^a   Legrand, Alain ^a   Delattre, Jacques ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Faculte de Pharmacie   (France)

Author keywords

Atherosclerosis; High density lipoproteins; Lipid peroxidation; Low density lipoproteins

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROPEROXIDE; HYDROXIDE; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; HUMAN; LIPID OXIDATION; LIPID PEROXIDATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

EID: 0342980342     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1999.139     Document Type: Review

References (106)

1. Witztum JL, Steinberg D. Role of oxidised low density lipoprotein in atherogenesis. J Clin Invest 1991; 88:1785-92.
2. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996; 20:707-27.
3. Gordon DJ, Probsfield JL, Garrison RJ, Neatoin JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79:8-15.
4. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high-density lipoprotein plasma fraction in cholesterol fed rabbits. J Clin Invest 1990; 85:1234-41.
5. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Cliff SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature 1991; 353:265-7.
6. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36:211-28.
7. Cockerill GW, Reed S. High density lipoprotein: multipotent effects on cells of the vasculature. Int Rev Cytol 1999; 188:257-97.
8. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15:1987-94.
9. Barter PJ. Inhibition of endothelial cell adhesion molecule expression by high density lipoproteins. Clin Exp Pharmacol Physiol 1997; 24:286-7.
10. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, et al. Monocytetransmigration induced by modification of low density lipoprotein in cocultures of human aortic-wall cells is due to induction of monocyte chemotactic protein-1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88:2039-46.
11. Cockerill GW, Saklatvala J, Ridley SH, Yarwood H, Miller NE, Oral B, et al. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vase Biol 1999; 19:910-7.
12. Parthasarathy S, Barnett J, Fong LG. High density lipoprotein inhibits oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990; 1044:275-83.
13. 2+-catalyzed oxidation of human low density lipoproteins. FEBS Lett 1989; 257:435-8.
14. Mackness MI, Abbott C, Arrol S, Durrington PN. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low density lipoprotein oxidation. Biochem J 1993; 294:829-34.
15. Christison JK, Rye KA, Stocker R. Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. J Lipid Res 1995; 36:2017-26.
16. Sattler W, Christison J, Stocker R. Cholesteryl ester hydroperoxide reducing activity associated with isolated high density lipoproteins. Free Radic Biol Med 1995; 18:421-9.
17. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104:129-35.
18. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96:2882-91.
19. Watson AD, Navab M., Hama SY, Sevanian A, Prescott SM, Stafforini DM, et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995; 95:774-82.
20. Stafforini DM, Zimrnerman GA, McIntyre TM, Prescott SM. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein. Trans Assoc Am Phys 1992; 105:44-63.
21. Klimov AN, Nikifora AA, Pleskov VM, Kuzmin AA, Kalashnikova NN, Antipova TO. Protective effect of high density lipoproteins, their subfractions, and lecithin-cholesterol acetyltransferase on the peroxidative modification of low density lipoproteins. Biokhimiia 1989; 54:118-23.
22. Vohl MC, Neville TA, Kimarathasan R, Braschi S, Sparks DL. A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation. Biochemistry 1999; 38:5976-81.
23. Banka CL. High density lipoprotein and lipoprotein oxidation. Curr Opin Lipidol 1996; 7:139-42.
24. Kunikate ST, Jarvis MR, Hamilton RL, Kane JP. Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci USA 1992; 89:6993-7.
25. Huang JM, Huang ZX, Zhu W. Mechanism of high-density lipoprotein subfractions inhibiting copper-catalayzed oxidation of low-density lipoproteins. Clin Biochem 1998; 31:537-43.
26. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7:69-76.
27. Laplaud PM, Dantoine T, Chapman MJ. Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses. Clin Chem Lab Med 1998; 36:431-41.
28. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. J Clin Invest 1998; 101:1581-90.
29. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vase Biol 1997; 17:1233-8.
30. Castellani LW, Navab M, van Lenten BJ, Hedrick CC, Hama SY, Goto AM, et al. Overexpression of apolipoprotein A-II in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest 1997; 100:464-74.
31. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet 1993; 3:73-6.
32. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52:598-608.
33. Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, Hokanson JE, et al. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol 1996; 16:1243-9.
34. Cao HB, Girard-Globa A, Serusclat A, Berbard S, Bondon P, et al. Lack of association between carotid intima-media thickness and paraoxonase gene polymorphism in non-insulin-dependent diabetes mellitus. Atherosclerosis 1998; 138:361-6.
35. Mackness MI, Arrol S, Mackness B, Durrington PN. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoproteins against lipid peroxidation. Lancet 1997; 349:851-2.
36. Mackness B, Mackness MI, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphism on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998; 423:57-60.
37. Cao H, Girard-Globa A, Berthezene F, Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism. J Lipid Res 1999; 40:133-9.
38. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19:3305-5.
39. van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Antiinflammatory HDL becomes proinflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96:2758-67.
40. Shih D, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284-7.
41. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999; 26:892-904.
42. Stremler KE, Stafforini DM, Prescott SM, Zimmerman GA, McIntyre TM. An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J Biol Chem 1989; 264:5331-4.
43. Stafforini DM, Prescott SM, Zimmerman GA, McIntyre TM. Mammalian platelet-activating factor acetylhydrolase. Biochim Biophys Acta 1996; 1301:161-73.
44. Dentan C, Lesnik P, Chapman MJ, Ninio E. PAF-acetherdegrading aceylhydrolase in plasma LDL is inactivated by copper-and cell-mediated oxidation. Arterioscler Thromb 1994; 14:353-60.
45. Tselepis AD, Dentan C, Karabina SAP, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL1 in human plasma catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995; 15:1764-73.
46. Tsoukatos DC, Arborati M, Liapikos T, Clay KL, Murphy RC, Chapman MJ, et al. Copper-catalyzed oxidation mediates PAF formation in human LDL subspecies. Protective role of PAF:acetylhydrolase in dense LDL. Arterioscler Thromb Vasc Biol 1997; 17:3505-12.
47. Goyal J, Wang K, Liu M, Subbaiah PV. Novel function of lecithin-cholesterol acyltransferase. Hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation. J Biol Chem 1997; 272:16231-9.
48. 2. Clin Biochem 1997; 30:221-5.
49. Klimov AN, Gurevich VS, Nikifora AA, Shatilina LV, Kuzmin AA, Plavinsky SL, et al. Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis 1993; 100:13-8.
50. Singh K, Chander R, Kapoor NK. High density lipoprotein subclasses inhibit low density lipoprotein oxidation. Indian J Biochem Biophys 1997; 34:313-8.
51. Gowri MS, van der Westhuyzens DR, Bridges SR, Anderson JW. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 1999; 19:2226-33.
52. Goulinet S, Chapman MJ. Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol 1997; 17:786-96.
53. Bowry VW, Stanley KK, Stocker R. High-density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992; 89:10316-20.
54. Tribble DL, van der Berg JJM, Motchnik PA, Ames BN, Lewis DM, Chait A, et al.. Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and α-tocopherol content. Proc Natl Acad Sci USA 1994; 91:1183-7.
55. Tribble DL, Chu BM, Gong EL, van Venrooij F, Nichols AV. HDL antioxidant effects as assessed using a nonexchangeable probe to monitor particle-specific peroxidative stress in LDL-HDL mixtures. J Lipid Res 1995; 36:2580-9.
56. .OH free radicals in the presence of oxygen. FEBS Lett 1997; 403:70-4.
57. Sattler W, Christison JK, Stocker R. Cholesteryl ester hydroperoxide reducing activity associated with isolated high-and low-density lipoproteins. Free Radic Biol Med 1995; 18:421-9.
58. Christison J, Karjalainen A, Brauman J, Bygrave F, Stocker R. Rapid reduction and removal of HDL-but not LDL-associated cholesteryl ester hydroperoxides by rat liver perfused in situ. Biochem J 1996; 314:739-42.
59. Hayek T, Oiknine J, Dankner G, Brook JG, Aviram M. HDL apolipoprotein A-I attenuates oxidative modification of low density lipoprotein: studies in transgenic mice. Eur J Clin Chem Clin Biochem 1995; 33:721-5.
60. Sue I, Escargueil-Blanc I, Troly M, Salvayre R, Nègre-Salvayre A. HDL and apo A prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vase Biol 1997; 17:2158-66.
61. Mashima R, Yamamoto Y, Yoshimura S. Reduction of phosphatidylcholine hydroperoxide by apolipoprotein A-I: purification of the hydroperoxide reducing proteins from human blood plasma. J Lipid Res 1998; 39:1133-40.
62. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins A-I and A-II. J Biol Chem 1998; 273:6088-95.
63. Graham A, Hassal DG, Rafique S, Owen JS. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis 1997; 135:193-204.
64. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony JA. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 1994; 33:832-9.
65. Nagano Y, Arai H, Kita T. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci USA 1991; 88:6457-61.
66. 2. free radicals. Radiat Res 1997; 147:721-8.
67. Salmon S, Santus R, Mazière JC, Aubailly M, Haigle J. Modified apolipoprotein pattern after irradiation of human high-density lipoproteins by ultraviolet B. Biochim Biophys Acta 1992; 1128:167-73.
68. Artola RL, Conde CB, Bagatolli L, Pecora RP, Fidelio GD, Kivatinitz SC. High-density lipoprotein from hypercholesterolemic animals has peroxidized lipids and oligomeric apolipoprotein A-I: its putative role in atherogenesis. Biochem Biophys Res Commun 1997; 239:570-4.
69. Hahn M, Subbiah MT. Significant association of lipid peroxidation products with high density lipoproteins. Biochem Mol Biol Int 1994; 33:699-704.
70. Bonnefont-Rousselot D, Motta C, Khalil A, Sola R, La Ville AE, Delattre J, et al. Physicochemical changes in human high-density lipoproteins (HDL) oxidized by gamma radiolysis-generated oxyradicals. Effect on their cholesterol effluxing capacity. Biochim Biophys Acta 1995; 1255:23-30.
71. Morel DW. Reduced cholesterol efflux to mildly oxidized high density lipoprotein. Biochem Biophys Res Commun 1994; 200:408-16.
72. Rifici VA, Khachadurian AK. Effects on dietary vitamin C and E supplementation on the copper-mediated oxidation of HDL and on HDL-mediated cholesterol efflux. Atherosclerosis 1996; 127:19-26.
73. Rifici VA, Khachadurian AK. Oxidation of high density lipoproteins: characterization and effects on cholesterol efflux from J774 macrophages. Biochim Biophys Acta 1996; 1299:87-94.
74. Salmon S, Mazière C, Auclair M, Theron L, Santus R, Mazière JC. Malondialdehyde modification and copper-induced autoxidation of high-density lipoprotein decrease cholesterol efflux from human cultured fibroblasts. Biochim Biophys Acta 1992; 1125:230-5.
75. Shoukry MI, Gong EL, Nichols AV. Apolipoprotein-lipid association in oxidatively modified HDL and LDL. Biochim Biophys Acta 1994; 1210:355-60.
76. Marcel YL, Jewer D, Leblond L, Weech PK, Milne RW. Lipid peroxidation changes the expression of specific epitopes of apolipoprotein A-I. J Biol Chem 1989; 264:19942-50.
77. Kritharides L, Jessup W, Mander EL, Dean RT. Apolipoprotein A-I-mediated efflux of sterols from oxidized LDL-loaded macrophages. Arterioscler Thromb Vasc Biol 1995; 15:276-89.
78. 3 leads to exposure of apo A-I and apo A-II epitopes and to formation of aldehyde protein adducts, and influences binding of oxidized low-density lipoprotein to type I and type III collagen in vitro. Biochem J 1998; 331:185-91.
79. Garner B, Witting PK, Waldeck AR, Christison JK, Raftery M, Stocker R. Oxidation of high density lipoproteins. I Formation of methionine sulfoxide in apolipoproteins A-I and A-II is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J Biol Chem 1998; 273:6080-7.
80. Cogny A, Paul JL, Atger V, Soni T, Moatti N. Structural changes of high-density-lipoprotein apolipoproteins following incubation with human polymorphonuclear cells. Eur J Biochem 1994; 222:965-73.
81. Cogny A, Paul JL, Surbled B, Atger V, Lenoble M, Moatti N. Oxidative modification of high-density lipoprotein3 induced by human polymorphonuclear neutrophils. Protective effect of pentoxyfilline. Eur J Biochem 1999; 259:32-9.
82. Gesquière L, Loreau N, Blache D. Impaired cellular cholesterol efflux by oxysterol-enriched high-density lipoproteins. Free Radic Biol Med 1997; 23:541-7.
83. Ueyama K, Yokode M, Arai H, Nagano Y, Li ZX, Cho M, et al. Cholesterol efflux effect of high density lipoprotein is impaired by whole cigarette smoke extracts through lipid peroxidation. Free Radic Biol Med 1998; 24:182-90.
84. 3. ArteriosclerThromb 1993; 13:958-66.
85. Therond P, Bonnefont-Rousselot D, Laureaux C, Vasson MP, Motta C, Legrand A, et al. Copper oxidation of in vitro dioleolylphosphatidylcholine-enriched high-density lipoproteins: physicochemical features and cholesteryl effluxing capacity. Arch Biochem Biophys 1999; 362:139-47.
86. Francis GA, Oram JF, Heinecke JW, Bierman EL. Oxidative tyrosylation of HDL enhances the depletion of cellular cholesterol esters by a mechanism independent of passive sterol desorption. Biochemistry 1996; 35:15888-97.
87. Bielicki JK, Forte TM, McCall MR. Minimally oxidized LDL is a potent inhibitor of lecithin:cholesterol acyltransferase activity. J Lipid Res 1996; 37:1012-21.
88. McCall MR, Tang JY, Bielicki JK, Forte TM. Inhibition of lecithin-cholesterol acyl-transferase and modification of HDL apolipoproteins by aldehydes. Arterioscler Thromb Vasc Biol 1995; 15:1599-606.
89. Davit-SpraulA, Thérond P, Leroy A, Palmade-Rieunier F, Roussel C, Moatti N, et al. Inhibition of lecithin cholesterol acyltransferase by phosphatidylcholine hydroperoxides. FEBS Lett 1999; 447:106-10.
90. Kamiyama S, Yamato T, Furukawa Y. Inhibitory effects of lipid oxidation on the activity of plasma lecithin-cholesterol acyltransferase. Biosci Biotechnol Biochem 1998; 62:941-6.
91. Musanti R, Ghiselli G. Interaction of oxidized HDL with J774-A-1 macrophages causes intracellular accumulation of unesterified cholesterol. Arterioscler Thromb Vasc Biol 1993; 13:1334-45.
92. Hurtado I, Fiol C, Gracia V, Caldú P. In vitro oxidised HDL exerts a cytotoxic effect on macrophages. Atherosclerosis 1996; 125:39-46.
93. Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovasc Pharmacol 1998; 32:52-13.
94. Martin-Nizard F, Squalli-Housaini H, Walters-Laporte E, Boullier A, Fruchart JC, Duriez P. Oxidized high-density lipoproteins modulate endothelin secretion by adult bovine aortic endothelial cells. J Cardiovasc Risk 1995; 2:263-7.
95. Ohmura H, Watanabe Y, Hatsumi C, Sato H, Daida H, Mokuno H, et al. Possible role of high susceptibility of high-density lipoprotein to lipid peroxidative modification and oxidized high-density lipoprotein in genesis of coronary artery spasm. Atherosclerosis 1999; 142:179-84.
96. Girona J, La Ville AE, Hears M, Olive S, Masana L. Oxidized lipoproteins including HDL and their lipid peroxidation products inhibit TNF-alpha secretion by TPH-1 human macrophages. Free Radic Biol Med 1997; 23:658-67.
97. Guertin F, Brunet S, Gavino V, Tuchweber B, Levy E. Malondialdehyde-modified high-density lipoprotein cholesterol: plasma removal, tissue distribution and biliary sterol secretion in rats. Biochim Biophys Acta 1994; 1214:137-42.
98. Guertin F, Brunet S, Lairon D, Levy E. Oxidative tyrosylation of high density lipoprotein impairs biliary sterol secretion in rats. Atherosclerosis 1997; 131:35-41.
99. Mazière JC, Myara I, Salmon S, Auclair M, Haigle J, Santus R, et al. Copper-and malondialdehyde-induced modification of high density lipoprotein and parallel loss of lecithin choleslerol acyltransferase activation. Atherosclerosis 1993; 104:213-9.
100. Guertin F, Brunei S, Gavino V, Tuchweber B, Levy E. Malondialdehyde-modified HDL leads to an accumulation of choleslerol in rat liver endothelial cells. Biochem Biophys Res Commun 1995; 212:1-8.
101. Laureaux C, Thérond P, Bonnefont-Rousselot D, Troupel SE, Legrand A, Delattre J. Alpha-tocopherol enrichment of high-densily lipoproteins: stabilization of hydroperoxides produced during copper oxidation. Free Radic Biol Med 1997; 22:185-94.
102. Cazzola R, Cervato G, Cestaro B. Variability in α-tocopherol antioxidant activity in the core and surface layers of low-and high-density lipoproteins. J Nutr Sci Vitaminol 1999; 45:39-48.
103. Dimitradis E, Griffin M, Collins P, Johnson A, Owens D, Tomkin GH. Lipoprotein composition in NIDDM: effects of dietary oleic acid on the composition, oxidisability and function of low and high density lipoproteins. Diabetologia 1996; 39:667-76.
104. Sola R, La Ville AE, Richard JL, Motta C, Bargallo MT, Girona J, et al. Oleic acid rich diet protects against the oxidative modification of high density lipoprotein. Free Radic Biol Med 1997; 22:1037-45.
105. Walters-Laporte E, Boullier A, Martin F, Teissier E, Decuypere L, Taccoen A, et al. Effect of α-tocopherol on HDL oxidation. Pharmacol Rev Commun 1998; 10:83-91.
106. Bowry VW, Stocker R. Tocopherol-mediated peroxidation. The prooxidant effect of vitamin E on the radical-initiated oxidation of human low-density lipoprotein. J Am Chem Soc 1993; 115:6029-44.